Clinical trials: Severe Asthma
Asthma
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies, regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as…
- Trial name
- NCT00858286
- Testing
- Spirometry, PEF measurements and diary cards to evaluate control of Asthma
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchial
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma
The study compares the efficacy and safety of FlutiForm® vs Flixotide® plus Foradil® in the treatment of severe persisent asthma in adult subjects.
- Trial name
- NCT00734318
- Testing
- Flutiform 250/10 micrograms, Flutiform 50/5 micrograms, Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms
- Where
- Hungary
- Volunteers
- 1,667 people
- Sponsor
- Mundipharma Research Limited
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes
Asthma is reported to affect between 3-14% of pregnancies making asthma medicines one of the most commonly used classes of medicines during pregnancy.
- Trial name
- NCT01681979
- Testing
- Fluticasone propionate (with and without concurrent salmeterol)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Asthma
Pilot Study of Magnesium Infusions in Pediatric Asthma
This is a prospective randomized pilot study that seeks to address the research question: In children with moderate-to-severe asthma, do intravenous magnesium infusions added to standard Pediatric intensive care unit (PICU)-level…
- Trial name
- NCT01522040
- Testing
- Magnesium Sulfate
- Where
- United States
- Sponsor
- University of Louisville
Asthma in Children
Alveolar and Serum sRAGE in Severe Asthma in Children
sRAGE is a recognized marker of alveolar injury in acute respiratory distress syndrome (ARDS). More recently, it seems to be an interesting marker in asthma.
- Trial name
- sRAGE (NCT05364996)
- Testing
- bronchial endoscopy with bronchoalveolar lavage (LBA), Blood sampling
- Where
- France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Clermont-Ferrand
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver…
- Trial name
- GRECO (NCT02918071)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Severe Asthma
Physical Activity Promotion and Clinical Remission in Severe Asthma
This study will investigate whether a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases objectively measured physical activity and the proportion of adults with…
- Trial name
- NCT07735494
- Testing
- Physical activity promotion, Tezepelumab
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Leeds
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients…
- Trial name
- NCT04410523
- Testing
- CSJ117
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Severe Asthma
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
- Trial name
- TAPER (NCT07363642)
- Testing
- Tezepelumab
- Where
- 75 sites in China
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Status Asthmaticus, Asthma (Diagnosis)
IV DEXAMETHASONE VS. METHYLPREDNISOLONE IN CHILDREN WITH SEVERE ASTHMA EXACERBATION
The study aims to determine whether a two-day intravenous course of dexamethasone is non-inferior to a conventional five-day intravenous course of methylprednisolone in children presenting with severe asthma exacerbations.
- Conditions
- Status Asthmaticus, Asthma (Diagnosis), Asthma Exacerbations
- Trial name
- IV:INTRAVENOUS (NCT07731217)
- Testing
- Intravenous Dexamethasone, Intravenous Methylprednisolone
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Istanbul Medeniyet University
Mild, Moderate and Severe Persistent Asthma as Defined by NHLBI-2 Guidelines
Asthma In-Home Monitoring (AIM) Trial
OBJECTIVE: Determine whether home asthma telemonitoring using store-and-forward technology improves outcomes when compared to in-person, office-based visits.
- Trial name
- NCT00282516
- Testing
- In-home telemonitoring of pediatric patients with persistent asthma
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Tripler Army Medical Center
Severe Prednisone Dependent Eosinophilic Asthma
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control
- Trial name
- NCT03470311
- Testing
- Benralizumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Asthma
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).
- Trial name
- READY-BREATHE (NCT07746687)
- Testing
- JNJ-95597528
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 440 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
A comparison of oral prednisolone administration with intravenous methylprednisolone infusion in the treatment of acute asthma exacerbation in hospitalized patients.
- Trial name
- NCT00627731
- Testing
- methylprednisolone sodium succinate (mPSL), prednisolone (PSL)
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Hamamatsu University
Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
- Trial name
- Tezepelumab (NCT06998095)
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Moderate to Severe Asthma
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment.
- Trial name
- EPIPHANY (NCT06385236)
- Testing
- Dupilumab, Benralizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego